texas-medical-center
(4)
Koda Health
Koda Health is a Houston-based digital health company that turns advance care planning into a guided, EMR-integrated digital experience. Its AI-enhanced platform helps health systems, payers, and providers scale goals-of-care conversations while letting patients create legally valid advance directives, DNR orders, and medical power-of-attorney documents at no cost. Founded in 2020 through the Texas Medical Center Biodesign program, Koda now reaches more than one million patients nationwide and pairs software with in-house clinical support to make sure care plans are understood and followed.
Tatiana Fofanova
Tatiana Fofanova is the co-founder and CEO of Koda Health, a Houston-based B2B enterprise SaaS company that helps health systems and payers scale advance care planning. Trained as a molecular-medicine PhD at Baylor College of Medicine and a former HHMI scholar, she left bench and pediatric work after concluding that patients needed access and good information more than newer drugs. She built Koda out of the Texas Medical Center's Biodesign Fellowship in 2020 with co-founders Desh Mohan and Katelin Cherry, describing the product as 'TurboTax meets Duolingo' for the hardest conversations in medicine. The company now supports more than a million patients nationwide and raised an oversubscribed $7M Series A in October 2025.
K2bio
K2bio is a Houston-based preclinical contract research organization (CRO) built on assets acquired from Bellicum Pharmaceuticals, including a certified mouse vivarium. It pairs full-service GLP and non-GLP in vivo and in vitro research with flexible private and shared lab space near the Texas Medical Center, giving early-stage biotech and pharma teams big-company infrastructure on small-company budgets.
Sporos Bioventures
Sporos Bioventures is a Houston-based private biotechnology company that builds and operates a portfolio of oncology and immune-disease startups under one roof. Rather than launching companies one at a time, Sporos pools capital, drug-discovery infrastructure, and operational expertise across multiple programs - including Tvardi Therapeutics, Asylia Therapeutics, Nirogy Therapeutics, Stellanova Therapeutics, and its internal Sporos BioDiscovery group - to move targeted cancer therapies from idea to early clinical trials faster and with less duplicated risk.